In Silico Studies with In Vivo Analysis and Post Mortem ADME-Tox Profiling in Mice

Katarzyna Stępnik,Wirginia Kukula-Koch,Anna Boguszewska-Czubara,Kinga Gawel
DOI: https://doi.org/10.3390/ijms25074021
IF: 5.6
2024-04-05
International Journal of Molecular Sciences
Abstract:Many people around the world suffer from neurodegenerative diseases associated with cognitive impairment. As life expectancy increases, this number is steadily rising. Therefore, it is extremely important to search for new treatment strategies and to discover new substances with potential neuroprotective and/or cognition-enhancing effects. This study focuses on investigating the potential of astragaloside IV (AIV), a triterpenoid saponin with proven acetylcholinesterase (AChE)-inhibiting activity naturally occurring in the root of Astragalus mongholicus, to attenuate memory impairment. Scopolamine (SCOP), an antagonist of muscarinic cholinergic receptors, and lipopolysaccharide (LPS), a trigger of neuroinflammation, were used to impair memory processes in the passive avoidance (PA) test in mice. This memory impairment in SCOP-treated mice was attenuated by prior intraperitoneal (ip) administration of AIV at a dose of 25 mg/kg. The attenuation of memory impairment by LPS was not observed. It can therefore be assumed that AIV does not reverse memory impairment by anti-inflammatory mechanisms, although this needs to be further verified. All doses of AIV tested did not affect baseline locomotor activity in mice. In the post mortem analysis by mass spectrometry of the body tissue of the mice, the highest content of AIV was found in the kidneys, then in the spleen and liver, and the lowest in the brain.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore the effect and mechanism of Astragaloside IV (AIV) as a potential memory enhancer. Specifically, the research aims to: 1. **Evaluate the impact of AIV on memory impairment**: By using Scopolamine (SCOP) and Lipopolysaccharide (LPS) to induce memory impairment in mice, study whether AIV can alleviate these impairments. SCOP is an antagonist of muscarinic cholinergic receptors and is often used to simulate cognitive dysfunction; LPS is a trigger factor for neuroinflammation. 2. **Analyze the pharmacokinetic and toxicity characteristics of AIV**: Through in - vivo and in - vitro experiments, study the absorption, distribution, metabolism, excretion (ADME) and toxicity characteristics of AIV in mice, especially its distribution in different organs, in order to evaluate its potential as a drug. 3. **Verify the mechanism of action of AIV**: Explore whether AIV improves memory impairment through anti - inflammatory mechanisms or other pathways. The study found that AIV at a dose of 25 mg/kg can significantly reduce the memory impairment caused by SCOP, but has no obvious effect on the memory impairment caused by LPS, indicating that AIV may not play a role through anti - inflammatory mechanisms. 4. **Evaluate the safety of AIV**: Study the impact of AIV on the motor activity of mice. The results show that AIV at all tested doses does not affect the basic motor activity of mice, indicating that it has good safety. Through these studies, the authors hope to provide a scientific basis for the development of new methods for treating cognitive disorders and neurodegenerative diseases.